These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease]. Maurel F; Lilliu H; Le Pen C Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770 [TBL] [Abstract][Full Text] [Related]
3. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia. Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335 [TBL] [Abstract][Full Text] [Related]
4. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study. Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722 [TBL] [Abstract][Full Text] [Related]
5. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606 [TBL] [Abstract][Full Text] [Related]
6. Resting tremor in Parkinson disease: a negative predictor of levodopa-induced dyskinesia. Kipfer S; Stephan MA; Schüpbach WM; Ballinari P; Kaelin-Lang A Arch Neurol; 2011 Aug; 68(8):1037-9. PubMed ID: 21825240 [TBL] [Abstract][Full Text] [Related]
7. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson's disease. Stathis P; Konitsiotis S; Tagaris G; Peterson D; Mov Disord; 2011 Feb; 26(2):264-70. PubMed ID: 21412833 [TBL] [Abstract][Full Text] [Related]
8. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Davis KL; Edin HM; Allen JK Mov Disord; 2010 Mar; 25(4):474-80. PubMed ID: 20131374 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311 [TBL] [Abstract][Full Text] [Related]
10. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial. Noyes K; Dick AW; Holloway RG; Med Decis Making; 2004; 24(5):472-85. PubMed ID: 15358996 [TBL] [Abstract][Full Text] [Related]
11. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy. Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615 [TBL] [Abstract][Full Text] [Related]
12. The role of sigma-receptors in levodopa-induced dyskinesia in patients with advanced Parkinson disease: a positron emission tomography study. Nimura T; Ando T; Yamaguchi K; Nakajima T; Shirane R; Itoh M; Tominaga T J Neurosurg; 2004 Apr; 100(4):606-10. PubMed ID: 15070112 [TBL] [Abstract][Full Text] [Related]
13. Onset and spread of dyskinesias and motor symptoms in Parkinson's disease. Fabbrini G; Defazio G; Colosimo C; Suppa A; Bloise M; Berardelli A Mov Disord; 2009 Oct; 24(14):2091-6. PubMed ID: 19691126 [TBL] [Abstract][Full Text] [Related]
14. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China. Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620 [TBL] [Abstract][Full Text] [Related]
15. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Thanvi B; Lo N; Robinson T Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069 [TBL] [Abstract][Full Text] [Related]